Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.
Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C. Dargaud Y, et al. Haemophilia. 2016 Jan;22 Suppl 1(Suppl 1):1-24. doi: 10.1111/hae.12860. Haemophilia. 2016. PMID: 26728503 Free PMC article.
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Liesner RJ, et al. Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16. Haemophilia. 2018. PMID: 28815880 Clinical Trial.
Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C, Katsarou O, Kotnik BF, Borel Derlon A, Schwarz R, Ypma PF, Matytsina I, Dey S, Schutgens REG. Escuriola Ettingshausen C, et al. Among authors: borel derlon a. Haemophilia. 2022 Jan;28(1):46-54. doi: 10.1111/hae.14454. Epub 2021 Nov 17. Haemophilia. 2022. PMID: 34791736 Free PMC article.
Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T; MHAI Study Group. d'Oiron R, et al. Semin Hematol. 2006 Jan;43(1 Suppl 1):S3-9. doi: 10.1053/j.seminhematol.2005.11.002. Semin Hematol. 2006. PMID: 16427382
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Borel-Derlon A, et al. J Thromb Haemost. 2007 Jun;5(6):1115-24. doi: 10.1111/j.1538-7836.2007.02562.x. J Thromb Haemost. 2007. PMID: 17403090 Free article. Clinical Trial.
60 results